PCM
KDNY

Penserra Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Penserra Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,025
Closed -$13K – 1611
2021
Q3 		$13K Buy
1,025
+10
+1% +$132 ﹤0.01% 1322
2021
Q2 		$14K Buy
1,015
+55
+6% +$880 ﹤0.01% 1245
2021
Q1 		$14K Sell
960
-5
-0.5% -$82 ﹤0.01% 1003
2020
Q4 		$15K Buy
+965
New +$14.6K ﹤0.01% 889

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Penserra Capital Management's KDNY Position: Q4 2021 in Review

Penserra Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2021, closing a stake of 1,025 shares — an estimated $13K sold.

Penserra Capital Management first reported a position in KDNY in Q4 2020 and held it in 4 quarters. The position peaked at $15K in Q4 2020. 103 funds tracked by Wall St. Rank hold KDNY as of Q4 2021.

  • Penserra Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,025 Chinook Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $13K.
  • Penserra Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $15K in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.